Cargando…
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
The annual cost of eculizumab maintenance therapy in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic–uremic syndrome (aHUS) exceeds $300,000 per patient. A better understanding of eculizumab pharmacokinetics and subsequent individual dose adjustment could reduce this cost. We measur...
Autores principales: | Gatault, Philippe, Brachet, Guillaume, Ternant, David, Degenne, Danielle, Récipon, Guillaume, Barbet, Christelle, Gyan, Emmanuel, Gouilleux-Gruart, Valérie, Bordes, Cécile, Farrell, Alexandra, Halimi, Jean Michel, Watier, Hervé |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966484/ https://www.ncbi.nlm.nih.gov/pubmed/26337866 http://dx.doi.org/10.1080/19420862.2015.1086049 |
Ejemplares similares
-
Finding the Right Heavy Chains for Immunostimulatory Antibodies
por: Boulard, Pierre, et al.
Publicado: (2022) -
Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients
por: Thibault, Gilles, et al.
Publicado: (2021) -
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
por: Dumet, Christophe, et al.
Publicado: (2019) -
Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review
por: Ramdani, Yanis, et al.
Publicado: (2022) -
The neonatal Fc receptor in cancer FcRn in cancer
por: Cadena Castaneda, Diana, et al.
Publicado: (2020)